Microfluidic Blood Prognosis Device
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining patient-specific prognoses for sickle cell disease are inadequate due to varying phenotypic manifestations and differing responses to treatments among patients, necessitating a more personalized approach for effective management.
Innovation Solution
A microfluidic microcirculation mimetic (MMM) device is used to analyze blood samples, featuring an inlet and outlet adhesion area with functionalizable surfaces to interact with red blood cells, and a pump system to control flow rates, allowing for the determination of cell detachment forces and adhesion indices, providing a patient-specific prognosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional prognosis methods are used for sickle cell disease, then treatment protocols are standardized, but patient-specific variability in phenotypic manifestations and treatment responses cannot be accounted for
Solution Approach 1:
The adhesion areas are selectively functionalized with specific chemicals (e.g., fibronectin, collagen, poly-D-lysine) to create locally differentiated surfaces that interact with red blood cells in patient-specific ways. This local functionalization enables the device to capture individual variations in cell adhesion properties, directly addressing the need for personalized prognosis while maintaining measurement precision.
Solution Approach 2:
The device measures and compares adhesion indices under multiple flow rate conditions (e.g., 10 µL/hr, 20 µL/hr, 30 µL/hr) to detect subtle patient-specific variations in red blood cell behavior. By changing the flow rate parameter and observing corresponding changes in adhesion patterns, the system achieves both personalization and accurate prognosis determination.
2Measurement precision
If a microfluidic MMM device is used to measure cell adhesion and detachment forces, then patient-specific prognoses can be obtained, but the device complexity increases compared to traditional methods
Solution Approach 1:
The microfluidic channel replicates the essential hemodynamic conditions of human microcirculation at a reduced scale, allowing accurate measurement of red blood cell adhesion and detachment forces without requiring complex in vivo or ex vivo systems. This scaled-down model maintains physiological relevance while simplifying the overall device structure and enabling precise prognosis measurements.
Solution Approach 2:
The single microfluidic device integrates multiple functions: it serves as both the adhesion substrate (through functionalized surfaces) and the flow control system (through the microfluidic channel and pump interface). This multi-functionality reduces the need for separate components, thereby decreasing device complexity while maintaining the capability to obtain precise patient-specific prognoses.
3Measurement precision
If functionalizable adhesion areas with surface treatments are used to interact with red blood cells, then adhesion indices can be quantified, but the manufacturing process becomes more complex
Solution Approach 1:
The adhesion areas are pre-functionalized with specific chemicals (fibronectin, collagen, poly-D-lysine) during device manufacturing or prior to use, establishing known adhesion properties before patient samples are introduced. This preliminary functionalization enables direct comparison of patient-specific adhesion indices against reference values, achieving precise measurements while streamlining the manufacturing process through standardized pre-treatment protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MMM device enables rapid, quantitative, and visual readouts that correlate with treatment efficacy, facilitating improved management of sickle cell disease by accounting for individual differences in blood conditions and drug responses.
Implementation Method 1
at least one of the inlet adhesion area or the outlet adhesion area includes a functionalizable adhesion area including one or more surface treatments of chemicals, the functionalizable adhesion area configured to interact with adherent red blood cells to a greater extent than non-adherent red blood cells based on a morphology of the red blood cells
Implementation Method 2
a pump configured to introduce the blood sample to the inlet adhesion area and to transfer the blood sample through the MMM device
Implementation Method 3
a microfluidic channel fluidically coupled with the inlet adhesion area to receive the blood sample from the inlet adhesion area
Data Source
AI summary
Systems and methods for providing patient-specific prognoses of blood conditions utilizing a microfluidic microcirculation mimetic (MMM) are described. In an aspect, an MMM device includes, but is not limited to, an inlet adhesion area configured to receive the blood sample; a microfluidic channel fluidically coupled with the inlet adhesion area to receive the blood sample from the inlet adhesion area; and an outlet adhesion area fluidically coupled with an outlet end of the microfluidic channel to receive the blood sample from the microfluidic channel, wherein at least one of the inlet adhesion area or the outlet adhesion area includes a functionalizable adhesion area including one or more surface treatments of chemicals, the functionalizable adhesion area configured to interact with adherent red blood cells to a greater extent than non-adherent red blood cells based on a morphology of the red blood cells.